The key is to identify a donor quickly and a related sample is preferred.
involves a donor to a patient in the case of bone marrow transplantation is a complex process depending on many factors, including the disease to be treated and the stage of the disease. increased survival rates have been correlated with the first treatment. Therefore, it is very important to identify a donor quickly.
In cases of blood cancer, there must be a balance found between the eradication of the disease and prevent rejection of the donor cells. The donor cells have the ability to seek and destroy cancer cells that are missed by chemotherapy and radiotherapy. This is most effective if the donor cells recognize the patient's cells as "foreign", which occurs if the tissue compatibility is not perfect. In some cases, it is preferable that the donor and recipient are not (100%) is ideal. The "aisle" that the disparity between the donor and the patient will increase the risk of graft rejection and attack the patient's healthy cells from donor cells (graft against host disease). During the transplant process doctors try to balance the benefits against the possible harm with an immunosuppressive drug in the bone marrow transplant procedure.
Although there are general guidelines for choosing a donor, specific requirements are decided by the transplant team. In general, a related donor is considered optimal. This is why a match is usually sought in the family first. A unit banked cord blood relatives (UCB) is the same as a family unit in the bone marrow. One reason for looking for a family is first of all that there are also minor proteins (HLA minor) that are important and relevant to them can lead to increased overall survival. These minor proteins are more common within a family. Although success with independent improves and in some cases, survival rates are similar, the preference is for a family member donation.
There are many studies that indicate that the related donors are better than unrelated, but it is important to note that an unrelated donor is better than no donor HLA typing and improved increased the rate of survival from independent sources. A recent study showed that the overall survival of 3 years in chronic lymphocytic leukemia (CLL) patients was higher with related donors matched compared with matched unrelated donors. A second study found that even a compatible related donor should be considered due to the easy and quick access to relatives and lower costs actually an option.